TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) have earned a consensus rating of "Buy" from the five analysts that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $12.67.

Several analysts have issued reports on the company. Wall Street Zen raised TuHURA Biosciences from a "sell" rating to a "hold" rating in a report on Friday. Brookline Capital Management raised TuHURA Biosciences to a "strong-buy" rating in a report on Monday, June 23rd. Finally, HC Wainwright reissued a "buy" rating and set a $12.00 price target on shares of TuHURA Biosciences in a report on Friday, May 16th.

TuHURA Biosciences Stock Performance

Shares of TuHURA Biosciences stock traded up $0.09 during midday trading on Friday, hitting $2.62. The company had a trading volume of 348,645 shares, compared to its average volume of 262,411. The company has a 50 day moving average of $2.81 and a 200 day moving average of $3.44. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.93.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02).

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invst LLC purchased a new position in TuHURA Biosciences in the 1st quarter worth $61,000. Jane Street Group LLC purchased a new position in shares of TuHURA Biosciences during the 1st quarter valued at about $69,000. Apollon Wealth Management LLC raised its stake in shares of TuHURA Biosciences by 86.0% during the 1st quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company's stock valued at $371,000 after buying an additional 53,154 shares during the last quarter. Sabal Trust CO purchased a new position in shares of TuHURA Biosciences during the 1st quarter valued at about $127,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of TuHURA Biosciences during the 4th quarter valued at about $54,000. Hedge funds and other institutional investors own 0.62% of the company's stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.